Despite delays in cannabis legalization efforts in the U.S., Tilray (NASDAQ: TLRY) still has its eyes on that prize.
The company’s CEO, Irwin Simon, told investors on the company’s earnings call that if the U.S. legalized medical marijuana, it would “represent an additional $250-million opportunity for Tilray.” He based that figure on…
Please login to read all 669 words.
